[1]张 瑜,路青华,曹海芳,等.聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响[J].医学信息,2021,34(17):114-116.[doi:10.3969/j.issn.1006-1959.2021.17.029]
　ZHANG Yu,LU Qing-hua,CAO Hai-fang,et al.Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B[J].Medical Information,2021,34(17):114-116.[doi:10.3969/j.issn.1006-1959.2021.17.029]
点击复制

聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年17期
页码:
114-116
栏目:
论著
出版日期:
2021-09-01

文章信息/Info

Title:
Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B
文章编号:
1006-1959（2021）17-0114-03
作者:
张 瑜; 路青华; 曹海芳; 等
（青海省第四人民医院肝病一科1，科教科2，青海 西宁 810000）
Author(s):
ZHANG Yu; LU Qing-hua; CAO Hai-fang; et al.
(Subject One,Department of Liver Disease1,Department of Science and Education2,the 4th People’s Hospital of Qinghai Province,Xining 810000,Qinghai,China)
关键词:
慢性乙型肝炎; 聚乙二醇干扰素; 恩替卡韦; 肝功能; 肝纤维化
Keywords:
Chronic hepatitis B; Polyethylene Glycol Interferon; PEG-IFN; Entecavir; Liver function; Liver fibrosis
分类号:
R512.6
DOI:
10.3969/j.issn.1006-1959.2021.17.029
文献标志码:
A
摘要:
目的 探讨聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响。方法 选择我院2019年1月-2020年1月收治的98例慢性乙型肝炎患者作为研究对象，按照随机数字表法分为观察组（n=49）和对照组（n=49）。对照组采用恩替卡韦治疗，观察组在此基础上联合聚乙二醇干扰素治疗，比较两组临床疗效、肝功能、肝纤维化及不良反应发生情况。结果 观察组总有效率为87.76%，高于对照组的65.31%，差异有统计学意义（P＜0.05）；治疗后，两组AST、ALT、TBIL、GCT水平及HA、PCⅢ、LN、Ⅳ-C水平均降低，且观察组于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 聚乙二醇干扰素联合恩替卡韦治疗慢性乙型肝炎临床疗效显著，可有效发挥抗病毒作用，改善患者肝功能状态，延缓肝纤维化进程，安全性良好。
Abstract:
Objective To investigate the effect of Polyethylene Glycol Interferon,PEG-IFN combined with entecavir on liver function and liver fibrosis in patients with chronic hepatitis B.Methods A total of 98 patients with chronic hepatitis B admitted to our hospital from January 2019 to January 2020 were selected as the research objects, and were divided into observation group (n=49) and control group (n=49) according to the random number table method.The control group was treated with Entecavir,on this basis, the observation group was combined with Polyethylene Glycol Interferon,PEG-IFN therapy to compare the clinical efficacy of the two groups, liver function , liver fibrosis and adverse reactions.Results The total effective rate of the observation group was 87.76%, which was higher than 65.31% of the control group,the difference was statistically significant (P＜0.05);After treatment, the two groups of AST, ALT, TBIL, GCT levels and HA, PCⅢ, LN, IV-C levels decreased, and the observation group was compared with the control group, the difference was statistically significant (P<0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion The combination of Polyethylene Glycol Interferon,PEG-IFN and entecavir has a significant clinical effect in the treatment of chronic hepatitis B. It can effectively exert antiviral effects, improve the liver function status of patients, delay the process of liver fibrosis, and has good safety.

参考文献/References:

[1]吴明山,刘振球,陈兴栋,等.全球乙型肝炎病毒基因型的分布现状[J].中华疾病控制杂志,2020,24(2):217-221. [2]陶军秀,李晓东,高小莲,等.抗病毒治疗慢性乙型肝炎患者的生存质量影响因素研究[J].中国全科医学,2019,22(23):2798-2804. [3]滕俊,陈竹,吴敬.恩替卡韦治疗乙型肝炎肝硬化的疗效观察[J].肝脏,2018,23(4):362-363,369. [4]杨东亮.丙氨酸转氨酶复常在乙型肝炎抗病毒治疗中的价值[J].中华肝脏病杂志,2019,27(10):741-747. [5]鲍旭丽,郭佳,顾娜,等.聚乙二醇干扰素联合核苷(酸)类似物临床治愈慢性乙型肝炎的分析[J].北京医学,2018,40(4):359-361. [6]郑伟,宋文渊,何强,等.核苷(酸)类药物初始抗病毒治疗慢性乙型肝炎患者144周疗效和对肾功能的影响[J].中华临床感染病杂志,2017,10(5):335-340. [7]陈胜,林昌锋,陈积武.肝苏片联合聚乙二醇化干扰素α2a治疗慢性乙型病毒性肝炎的疗效观察[J].现代药物与临床,2018,33(8):2065-2069. [8]中华医学会肝病学分会.慢性乙型肝炎诊断标准（2015年版）[J].中西医结合肝病杂志,2015,25(6):384. [9]曾艳丽,魏君锋,宋晨馨,等.慢性乙型肝炎患者乙型肝炎病毒核心抗体与肝脏炎症程度的相关性分析[J].中华实用诊断与治疗杂志,2018,32(7):642-645. [10]鲍腾,胡庆刚,叶珺,等. HBsAg水平在慢性HBV感染者疾病进展中的动态监测价值[J].临床肝胆病杂志,2017,33(8):1475-1478. [11]宁琴.慢性乙型肝炎临床治愈(功能性治愈)专家共识[J].临床肝胆病杂志,2019,35(8):1693-1701. [12]赵云,朱培福.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能、HBV-DNA和肝纤维化指标的影响[J].河北医药,2018,40(5):759-761. [13]王永力,吴文煜,尤洁,等.核苷(酸)类似物经治慢性乙型肝炎患者干扰素α治疗过程中细胞因子信号抑制因子3的表达与抗病毒疗效的关系[J].中华肝脏病杂志,2019,27(1):27-32. [14]王健.恩替卡韦联合聚乙二醇干扰素治疗慢性乙型肝炎的疗效及安全性评价[J].中国医药科学,2020,10(4):71-74.

相似文献/References:

[1]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和 生活质量的影响研究[J].医学信息,2018,31(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
　LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,31(17):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
　LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,31(17):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
　WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,31(17):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[4]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,31(17):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[5]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
　WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,32(17):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[6]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
　FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(17):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[7]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,32(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
　ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(17):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[8]罗 丹,梁惠卿,吴耀南.吴耀南教授基于“伏邪”理论治疗慢性乙肝的验案举隅[J].医学信息,2019,32(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[9]周腾腾,郑 莹,梁恵卿,等.蛋白质组学在慢性乙型肝炎常见中医证型中的研究[J].医学信息,2019,32(20):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
　ZHOU Teng-teng,ZHENG Ying,LIANG Hui-qing,et al.Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B[J].Medical Information,2019,32(17):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
[10]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].医学信息,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
　CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,32(17):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
[11]王雪云,孙 敏,赵巧云,等.聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察[J].医学信息,2020,33(04):144.[doi:10.3969/j.issn.1006-1959.2020.04.046]
　WANG Xue-yun,SUN Min,ZHAO Qiao-yun,et al.Observation on the Efficacy of Pegylated Interferon Combined with Tenofovir Fumarate in the Treatment of Chronic Hepatitis B[J].Medical Information,2020,33(17):144.[doi:10.3969/j.issn.1006-1959.2020.04.046]

更新日期/Last Update: 1900-01-01